Tiziana Life Sciences Ltd (TLSA)
NASDAQ: TLSA · Real-Time Price · USD
1.740
-0.030 (-1.69%)
At close: Dec 5, 2025, 4:00 PM EST
1.740
0.00 (-0.02%)
After-hours: Dec 5, 2025, 7:34 PM EST
Tiziana Life Sciences Employees
Tiziana Life Sciences had 9 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
9
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,426,778
Market Cap
206.75M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TLSA News
- 3 days ago - Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company - GlobeNewsWire
- 10 days ago - Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program - GlobeNewsWire
- 22 days ago - Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Tiziana Life Sciences: Foralumab's Intranasal Push Is A Good Moonshot - Seeking Alpha
- 5 weeks ago - Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy - GlobeNewsWire
- 2 months ago - Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia - GlobeNewsWire
- 2 months ago - Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress - GlobeNewsWire
- 2 months ago - Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury - GlobeNewsWire